Evogene's Strategic Transformation and Financial Overview for Q2 2026

Evogene Ltd., a leader in computational chemistry focused on the design of small molecules for agriculture and pharmaceuticals, has released its financial results for the second quarter and the first half of 2026, revealing a company that is well on its way to achieving its strategic transformation initiated in 2025.

Strategic Shift Towards AI-driven Computational Chemistry

Evogene's evolution over the past 18 months has been marked by a significant pivot to a streamlined, AI-focused operational model. Having reduced its workforce from 117 employees in December 2024 to just 38 by August 2026, the company has also aligned its operations to focus on higher value and commercially viable projects. This focus is projected to lower Evogene's annual cash burn to around $8.5–$9.5 million for 2026, down from $14.4 million in the previous year.

The company's strategy capitalizes on leveraging artificial intelligence to accelerate drug discovery and agricultural product development. The integration of AI within their operational processes aims to enhance efficiency and discovery speed, as the company expands its chemical space to approximately 110 billion molecules available for exploration through its proprietary platform, ChemPass AI™.

Financial Progress and Collaborations

Evogene's financial results showcase an encouraging narrative. In the second quarter of 2026, the company reported a net loss of approximately $1.8 million—a substantial decrease compared to the $4.7 million loss reported in Q2 2025. Collaboratively, Evogene has secured six active partnerships with leading biotechnology firms and esteemed academic institutions, enhancing its research capabilities and broadening its R&D efforts.

Since the start of 2026, Evogene has engaged in multiple new collaborations, indicating robust confidence in their AI-driven methodologies. Two significant programs, already past the Hit Identification stage, have yielded promising validation results that surpass partner expectations, setting the stage for further development.

Advancements in Internal Drug Discovery

In tandem with external collaborations, Evogene is making strides in its internal drug discovery efforts. The program has recently progressed from the Hit-to-Lead stage into Lead Optimization, focusing on creating proprietary molecules, which are likely candidates for future preclinical testing.

In the agricultural sector, Evogene is advancing its control program for Septoria, a prevalent fungal disease, now nearing completion of its Lead Optimization phase. This phase involves rigorous biological testing of synthesized molecules ahead of subsequent greenhouse and field trials.

Expansion of ChemPass AI™ Capabilities

In an ongoing effort to enhance its computational platform, Evogene has integrated advanced AI agents within its ChemPass AI workflow, thanks to a collaboration with Google Cloud. These AI systems are designed to automate intricate research processes, dramatically reducing the time required for tasks that previously would take weeks.

Evogene's recent launch of the Antifungal Potency Predictor (APP) further enriches its toolset, enabling precise predictions of small molecule activities against fungal pathogens, thereby enriching their developmental capabilities.

Strategic Portfolio Optimization

In a bid to maintain a concentrated focus, Evogene has decided to divest itself from several non-core activities. Most notably, the company has ceased operations with Lavie Bio following the sale of its key assets and has transitioned Biomica to a discontinued operation after successfully licensing its oncology candidate BMC128. This streamlined approach underscores Evogene’s commitment to focusing resources on high-risk, high-reward opportunities in both the pharmaceutical and agricultural sectors.

Management's Outlook

Ofer Haviv, President and CEO of Evogene, affirmed the company's transformative journey, highlighting their transition toward a focused, AI-driven approach to computational chemistry. The validation gained through expanding commercial partnerships and technological progress, especially in ChemPass AI, supports Evogene's ambitions for long-term value creation.

Looking forward, Evogene aims to not only advance its pharmaceutical and agricultural projects but also strengthen its collaborations with top-tier biotechnology companies, thereby solidifying its position in the advanced computational chemistry landscape.

Overall, Evogene's recent financial results and strategic initiatives represent a promising trajectory in its quest to leverage the power of artificial intelligence within the lifecycle of drug and agrochemical discovery, marking a new chapter in its operational saga.